Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

February 29, 2024

https://www.globenewswire.com/news-release/2024/02/29/2838394/0/en/Vigil-Presents-Poster-on-Impacts-of-Misdiagnosis-and-Genetic-Testing-on-Adult-Onset-Leukoencephalopathy-with-Axonal-Spheroids-and-Pigmented-Glia-ALSP-Patient-Journey-at-ACTRIMS-202.html

Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients’ barriers to genetic testing

WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) —  Vigil Neuroscience, Inc. (Nasdaq:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented a poster detailing the impact of misdiagnosis and the importance of genetic testing at the 2024 ACTRIMS Forum being held in West Palm Beach, Florida, from February 29 – March 2.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.